"Rituximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069283
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785
|
| Concept/Terms |
Rituximab- Rituximab
- CD20 Antibody, Rituximab
- Rituximab CD20 Antibody
|
Below are MeSH descriptors whose meaning is more general than "Rituximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Rituximab [D12.776.124.486.485.114.224.075.785]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Rituximab [D12.776.124.790.651.114.224.075.785]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Rituximab [D12.776.377.715.548.114.224.284.785]
Below are MeSH descriptors whose meaning is more specific than "Rituximab".
This graph shows the total number of publications written about "Rituximab" by people in this website by year, and whether "Rituximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 3 | 4 |
| 2016 | 4 | 4 | 8 |
| 2017 | 36 | 39 | 75 |
| 2018 | 41 | 33 | 74 |
| 2019 | 13 | 21 | 34 |
| 2020 | 9 | 17 | 26 |
| 2021 | 13 | 11 | 24 |
To return to the timeline, click here.
Below are the most recent publications written about "Rituximab" by people in Profiles.
-
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. Eur J Immunol. 2021 10; 51(10):2478-2484.
-
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. Nephrol Dial Transplant. 2021 08 27; 36(9):1758-1760.
-
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry. Neurol Neuroimmunol Neuroinflamm. 2021 09; 8(5).
-
Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. Rheumatol Int. 2021 Oct; 41(10):1839-1843.
-
Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery. Int J Mol Sci. 2021 Aug 18; 22(16).
-
Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab. BMJ Case Rep. 2021 Aug 03; 14(8).
-
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli et al. Ann Rheum Dis. 2021 10; 80(10):e166.
-
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al. Ann Rheum Dis. 2021 10; 80(10):e165.
-
Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al. Ann Rheum Dis. 2021 10; 80(10):e167.
-
What should we do about vaccination of patients on anti-CD20 antibody therapy? J Neurol Neurosurg Psychiatry. 2022 01; 93(1):4.